Study Locations and Site Identification
Country and clinical site selection are critical to clinical study success, influencing patient recruitment, regulatory timelines, data quality, operational efficiency, and overall study cost. Using AI-driven analytics, AC can identify, specific to your studies taget indication and phase of development, the most suitable countries and high-performing clinical sites based on patient availability, investigator performance, competitive trial activity, regulatory efficiency, and historical study outcomes — enabling biotech companies to accelerate development, reduce risk, and generate high-quality, globally acceptable clinical data.
The people at Armstrong Clinical have themselves selected studies involving over 30 countries and hundreds of sites across all phases of development. We understand the importance of quality, cost, time and experience in selecting the resdearch sites.
Our approach, combining data analytics and global experts who understand the geographic cost, regulatory, and timeline considerations, helps reduce operational risk, improve study timelines, optimise patient recruitment, and ensure alignment among the study strategy, enabling biotech companies to accelerate development, reduce risk, and generate high-quality, globally acceptable clinical data.
